Proactive investors

e-Therapeutics is a drug discovery and development company. The company possesses efficient proprietary methods for discovering new bioactive compounds, de-risking candidates against efficacy and safety, discovering combinations of compounds with specific therapeutic effects, and discovering surprising new indications for existing compounds.

Systematic Drug Discovery

3D Network Graphic of the interactions between proteins in the bacterium Streptococcus pneumoniae

Scientific advances in complex systems science at Oxford and Newcastle Universities led to the foundation of e-Therapeutics. Our scientists discovered methods for untangling complex biological networks to show their functional structure, and methods for accurately predicting and explaining the effects of multiple interventions in a complex network. Multiple interventions sometimes cause highly counterintuitive, difficult-to-predict effects, such as the bizarre “paradoxical restorations” in neurology. The original application of these methods was in neurology.

The application of these methods to drug discovery began in 2003. Almost all the processes that underlie life and disease are mediated by complex networks of interaction between proteins and other molecules. e-Therapeutics’ methods are a powerful platform for understanding what the structure of these networks means for function, dysfunction and mitigation.

In addition, drug molecules affect multiple proteins and not just their primary target. Because of these multiple interventions in complex networks, the biological effects of a molecule's interactions with pathogenic, pathological and normal cells have historically been very difficult to predict.

e-Therapeutics’ quantitative methods for calculating the effect of a molecule’s multiple interventions in the networks within very many different cell-types enables a new approach to evaluating the efficacy and safety of molecules very early in development, and a new approach to searching for compounds that bring benefit to patients who are poorly treated by current medicines.


Drug Discovery Programme

e-Therapeutics proprietary discovery program is focused on areas of high unmet medical need, for which there are good quality proteomics data. Discovery projects are underway in Alzheimer’s dementia, age-related macular degeneration, atherosclerosis, prostate cancer, and pain, in partnership with several companies.


Drug development programme

e-Therapeutics is developing candidate new medicines in anti-infectives, depression, respiratory disorders, atherosclerosis, pain, and cancer.

The antiinfective projects are a topical antibiotic for resistant gram-positive infections (ETX1153a: Mersanex), which is partnered for registration trials in India with Klab, an I.V. antibiotic for acute hospital based bacteraemia (ETX1153b: Amersib), and an oral medicine to treat Clostridium difficile overgrowth (ETX1153c: Clostriban).

The antidepressant (ETS6103: Viotra) has shown pleasing efficacy and safety features in Phase II, and is partnered for registration trials in India with Klab.

ETX9101 (Orovair) is designed as an oral once-daily that reduces the risk of exacerbation in inflammatory respiratory disease. It has shown pleasing efficacy and safety features in Phase II, and is partnered for registration trials in India with Klab.

ETX6107 is designed as a quadrivalent treatment for atherosclerosis which lowers LDL cholesterol, diminishes vascular inflammation, reduces carbohydrate cardiovascular risk factors, and has anti-adipogenic features. It is intended that it will enter an initial clinical effectiveness trial in 2010, with Infinitus Clinical Research.

ETX6218 is intended to provide a multivalent treatment option for fibromyalgia, in which chronic pain, tender points, sleep disturbance and depression are addressed. It is intended that it will enter an initial clinical effectiveness trial in 2010, with Infinitus Clinical Research.

ETS2101 is a novel chemotherapy for metastatic melanoma that has shown promise in preclinical testing, being more potent than cisplatin in multiple cell-lines. It is a selective apoptotic and not a cytotoxic, which effectively turns back on the self-destruct mechanism in cells that are so badly damaged that this mechanism has failed. Such cells are almost exclusively cancer cells, and so the candidate carries a low burden of side effects. It is intended that it will enter an initial clinical effectiveness trial in multiple metastatic cancers in 2010, with Infinitus Clinical Research.


Candidate evaluation programme

Drug development, especially in its clinical stages is expensive. It is also very risky, since the great majority of candidates that are evaluated in clinical trials fail. The two principal risks lie in efficacy and safety, and the information derived for IND filings prior to clinical stages plainly does not adequately predict efficacy and safety in Man, evidenced by the large number of late stage failures.

e-Therapeutics provides a different approach to de-risking molecules for efficacy and safety, based on its ability to evaluate quantitatively the effect of a molecule on target cell types, and on non-target, normal cell types.

This evaluation service is used as a decision support tool by investors prior to investment or to guide investment decisions, and pharmaceutical companies prior to investing their resources in clinical programmes for candidates developed in-house or before in-licensing candidates.

e-Therapeutics evaluation is also used to help determine the mode of action of molecules, to identify appropriate positioning against competitive drugs, and to identify and characterise possible drug interactions.

e-Therapeutics sometimes uses these capabilities to evaluate canadidates for acquisition into the company’s own proprietary pipeline.

Professor Malcolm Young - CEO
Professor Malcolm Young is a scientist by background. He has recently been Director of the Complex Systems Group; Director of the Institute for Neuroscience; Provost of the Faculty of Science, Agriculture and Engineering; and Pro-Vice Chancellor for Strategic Development at Newcastle University, after having been a Royal Society Research Fellow at the RIKEN Institute in Japan, and at Oxford University. His research expertise lies in complex systems analysis and informatics, and his research outputs include 6 publications in Nature and Science and 12 in Proceedings and Philosophical Transactions of the Royal Society. The main goals of his research were to understand how biological function arises from structural aspects of complex biological systems. He is one of eighteen scientists worldwide nominated by the Sunday Times as the "Brains behind the 21st Century". Professor Young founded e-Therapeutics, and has led its development since.


Steve Self - Development Director
Steve Self began his career in Chemistry in 1975 with The Wellcome Foundation. He held positions in both R&D and Operations before being appointed as a full time Project Manager in Wellcome Research in 1987. He became Head of Project management in 1991, and was appointed Group Vice-President for Project Management in 1993. Steve Joined Boots Healthcare International in 1995 as Head of Respiratory and Analgesic product development, before joining Merck Generics in 1997 as European Technical Director. He was appointed as MGG’s Group R&D Director in 1999, and stayed with Merck until the sale of the company to Mylan in 2007. Since then he has worked for a private equity bank on major US pharmaceutical acquisitions, before joining e-Therapeutics to drive the Company’s clinical development activities.


Johnny Cordiner - Commercial and Finance Director
Johnny Cordiner is an experienced investment banker who specialised in life sciences and in oil and gas. Johnny is a graduate chemist, a member of the Institute of Chartered Accountants for Scotland, and a member of the Securities Institute. He gained fifteen years business experience in a number of financial roles, including working in industry, management consulting and offshore banking before entering investment banking. Johnny has been instrumental in the commercialisation of e-Therapeutics, having worked with Professor Young and Dr Drucker for more than three years to place the company in a sound financial and strategic position for rapid development.


Professor Oliver Francis Wintour James - Non-executive Chairman
Oliver has been a non-executive director of BUPA since 1999 and was a non-executive director of Goldsborough Health Care plc from when it floated on the main market in 1995, until it was acquired by BUPA in 1997. He has also been a non-executive director of the Newcastle upon Tyne Hospitals NHS Foundation Trust since 2006. Oliver qualified as a physician in 1975 and practised until 2004 when he became Head of the medical faculty at Newcastle University. He was Senior Vice President of the Royal College of Physicians from 1997 to 1999, and has been a member of many national and governmental medical related boards and committees. Oliver joined the Company as a non-executive director in October 2007.


Mr Brad Hoy - Non-executive Director
Brad has over fifteen years of commercial experience in the pharmaceutical and biotechnology industries through financial and general management roles in the UK and USA. Brad is Director and co-founder of Seven Hills Venture Partners Ltd, a life sciences advisory firm based in Edinburgh. Previously Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed speciality pharmaceutical company, Chief Executive Officer of Xcellsyz Ltd, a UK venture capital-backed life science company, and Senior Director of Geron Corporation’s stem cell-focussed UK subsidiary. Prior to co-founding Seven Hills, Brad was Chief Financial Officer at Cyclacel Ltd, a UK oncology company, and he held senior financial management positions at ChiRex Inc, a US-based pharmaceutical CMO. Brad is a Chartered Management Accountant.

Number of Securities in Issue

The Company’s share capital consists of an issued share capital of 65,420,292 ordinary shares in issue, with a nominal value of 0.1 pence each (”Ordinary Shares”), each share having equal voting rights. The company does not hold any Ordinary Shares in treasury. So far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 77.48%. At 11 November 2009, the following interests of shareholders in excess of 3% (significant shareholders), have been notified to the company:


Significant Shareholders and shareholdings :

* Credit Suisse Client Nominees (UK) Limited is the nominee for RAB Special Situations (Master) Fund LLP- 16,357,950 (25.00%)

* Newcastle University Holdings Limited - 6,744,000 (10.31%)

* Octopus Group – 3,119,070 (4.77%)

* Pershing Nominees Limited – 3,180,108 (4.86%)

* Gartmore Investment Limited – 6,541,000 (9.998%)

* Malcolm Young - 20,620,482 (31.52%)

Updated on 5th January 2011

• ABM Resources (ASX: ABU)
• Algae.Tec (ASX: AEB)
• Allocate Software (AIM: ALL)
• Altus Strategies (AIM: Altus)
• Anglo Asian Mining (AIM: AAZ)
• Apella Resources Inc. (TSX-V: .APA)
• Arafura Resources (ASX: ARU)
• Argos Resources (AIM: ARG)
• ASX:BTV (ASX: BTV)
• Aura Energy Limited (ASX: AEE)
• Auzex Resources Limited (ASX: AZX)
• Avalon Rare Metals (TSX: AVL)
• Baobab Resources (AIM: BAO )
• Batavia Mining (ASX: BTV)
• Beowulf Mining plc (AIM: BEM)
• Cadillac Ventures, Inc (TSX-V: CDC)
• Camco (AIM: CAO )
• Central Petroleum (ASX: CTP)
• Cockatoo Coal (ASX: COK)
• Condor Resources (AIM: CNR)
• Continental Coal (ASX: CCC)
• Copper Fox Metals (TSX-V: CUU)
• Deltex Medical Group plc (AIM: DEMG)
• Dragon Mining (ASX: DRA)
• Dragon Oil (LSE / ISE: DGO)
• Eastmain Resources (TSX: ER)
• Eco Animal Health Group Plc (AIM: EAH)
• ECR Minerals (AIM: ECR)
• Elementos (ASX: ELT)
• Emmerson Resources (ASX: .ERM)
• Envirogold (ASX: EVG)
• Epistem (AIM: EHP)
• EurOmax Resources (TSX-V: EOX)
• Eurotin Inc. (TSX-V: ERT.P)
• Forte Energy (AIM / ASX: FTE)
• Frontier Rare Earths (TSX: FRO)
• Genesis Resources (ASX: GES)
• Gowest Gold (TSX-V: GWA)
• Great Western Minerals Group (TSX-V: GWG)
• Greenearth Energy Ltd. (ASX: .GER)
• Groote Resources (ASX: GOT)
• Gryphon Minerals (ASX: GRY)
• Gulf Resources (ASX: GLF)
• Halo Resources (TSX-V: HLO)
• Helius Energy Plc (AIM: HEGY)
• Icon Resources Limited (ASX: .III)
• IGas Energy Plc (AIM: IGAS)
• India Resources Ltd (ASX: IRL)
• Ironbark Zinc Limited (ASX: IBG)
• Ironclad Mining (ASX: IFE)
• IXR Resources (ASX: IXR)
• Jupiter Energy (ASX: JPR)
• Kalahari Resources Inc. (TSX-V: .KLA)
• Kentor Gold (ASX: KGL)
• Kiotech International (AIM: KIO)
• Knick Exploration (TSX-V: KNX)
• Legend Mining (ASX: LEG)
• Li3 Energy (OTCBB: LIEG)
• Metallica Minerals Ltd (ASX: .MLM)
• Millennium Minerals Limited (ASX: MOY)
• Millrock Resources (TSX-V: MRO)
• Mosquito Consolidated Gold Mines (TSX-V: MSQ)
• Mountain Lake Resources (TSX-V: MOA )
• Mutiny Gold (ASX: MYG)
• National Milk Records (PLUS: NMRP)
• Natural Resources USA Corporation (OTCBB: NTRC)
• NGM Resources (ASX: NGM)
• North River Resources (AIM: NRRP)
• NQ Exploration Inc (TSX-V: NQE)
• Ord River Resources Ltd (ASX: ORD)
• Orko Silver (TSX-V: OK)
• Ormonde Mining plc (AIM: ORM)
• Orosur Mining Inc. (AIM / TSX-V: OMI)
• Osceola Hydrocarbons (PLUS: OSCE)
• Ovoca Gold (AIM : OVG )
• Oxford Nutrascience (AIM: ONG)
• Peninsula Minerals (ASX: PEN)
• Petroceltic International (AIM: PCI)
• Planet Payment (AIM: PPT)
• Plato Gold Corp (TSX-V: PGC)
• Prosperity Minerals Holdings Limited (AIM: PMHL)
• Pulse Health Limited (ASX: .PHG)
• Pure Energy (TSX-V: PEV)
• Ram Resources (ASX : RMR)
• Range Resources (AIM / ASX: RRL)
• Renovo Group Plc (LSE: RNVO)
• Resource Generation (ASX: RES)
• Rexahn Pharmaceuticals (AMEX: RNN)
• Rey Resources (ASX: .REY)
• Riverside Resources (TSX-V: RRI)
• Rodinia Minerals (TSX-V: .RM)
• SeaEnergy PLC (AIM: SEA)
• Selwyn Resources (TSX-V: .SWN)
• Senetek (OTCBB: SNKTY)
• Shaw River Resources (ASX: SRR)
• Shree Minerals (ASX: SHH)
• Siburan Resources (ASX: SBU)
• Silver Lake Resources (ASX: SLR)
• Simba Energy (TSX-V: SMB)
• Solo Oil (AIM: SOLO)
• Specialist Energy Group (AIM: SEGR)
• St. Elias Mines (TSX-V: SLI)
• Stellar Resources (ASX: SRZ)
• Sumatra Copper & Gold (ASX: SUM)
• Sun Resources (ASX: SUR)
• Syndicated Metals (ASX: SMD)
• Tantalus Rare Earths (XETRA: TAE)
• Tarsis Resources (TSX-V: .TCC)
• Thor Mining (AIM / ASX: THR)
• Thundelarra Exploration (ASX: THX)
• Urals Energy (AIM: UEN)
• US Nickel (ASX: USN)
• Wessex Exploration (PLUS: WX.P)
• Westgold Resources Limited (ASX: WGR)
• YTC Resources (ASX: YTC)